This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Andrew Bradbury, MD, PhD
Chief Scientific Officer at Specifica


Andrew Bradbury has worked in the field of phage display and antibody engineering for almost thirty years. His present research interests lie in improving in vitro display technologies, and antibody library quality, in order to make in vitro antibody selection the preferred method to generate highly specific, high affinity antibodies. Within this context he has developed an antibody selection pipeline that combines phage and yeast display in methods that exploit the advantages of each. Andrew did a PhD with Cesar Milstein, became a tenured assistant professor at SISSA in Italy, and was a Scientist 5 and Group Leader at LANL before retiring to join Specifica as CSO in 2017. Specifica focusses on the use of next generation sequencing to generate the highest quality antibody libraries.